STAT COURSE 2015

19.21 NOVEMBER 2015 MEXICO



SIMULTANEOUS TRANSLATION ENGLISH · SPANISH · ENGLISH

The Latin American Cooperative Oncology Group (LACOG) is organizing the 3rd Latin American Course on Methodology applied to clinical research in Oncology.

AIMS OF THE COURSE & LEARNING OBJECTIVES

The course is designed to offer an introduction to the statistical principles and methodological aspects involving the design and analysis of clinical trials. It will give insight in the principles of clinical trial development, treatments and biomarkers investigation, as well as understand and critically review its methods and results.

Upon completion of this course, attendees should be able to:

- Understand the concepts and statistical methods required in biological and health Science research
- · Interpret study results as routinely presented in the scientific literature considering the design and analysis issues

DATE & LOCATION

19-21 November 2015

INCan - Instituto Nacional de Cancerología de Mexico Nueva Torre de hospitalización

del Instituto Nacional de Cancerología. 4to. Piso, Área Académica, Av. San Fernando 2, CP 14080, Tlalpan, D.F.

More information at www.lacog.org.br.

TARGET AUDIENCE

Statisticians, epidemiologists, medical doctors, nurses, pharmacists, and all who have been working with clinical trials in Latin America.

PRELIMINARY COURSE PROGRAMME

DAY 1 PRINCIPLES OF STATISTIC

Thursday 19th, November 2015

8:00-8:25	Registration
8:25-8:30	Welcome and introduction - G. Werutsky (BR)
8:30-9:15	Epidemiology in oncology research - A. Mohar (MX)
9:15-10:00	Current status of cancer clinical research in Brazil and Latin America: an overview - G. Werutsky (BR)
10:00-10:10	Discussion
Coffee break	
10:30-11:15	General introduction to hypothesis tests and clinical trials statistics - R. Parker (USA)
11:15-12:00	Endpoints and design of Phase III trials - S. Litière (BE)
12:00-12:10	Discussion
Lunch	
13:15-14:00	Sample size for phase III trials - L. Collette (BE)
14:00-14:45	Analysis of time to event endpoints in oncology - R. Parker (USA)
14:45-14:55	Discussion
Coffee break	
15:15-16:00	Non - Inferiority trial: design, concepts and issues - S. Halabi (USA)
16:00-16:45	Common problems in analysis and reporting of studies (Bias, ITT, multiple tests) - L. Collette (BE)

DAY 2 CLINICAL TRIALS DESIGN AND ANALYSIS

Friday 20th, November 2015

16:45-16:55 Discussion

8:30-9:15	Data monitoring and early stopping rules in phase III studies - R. Parker (USA)	
9:15-10:00	Design and analysis of phase I trials - L. Collette (BE)	
10:00-10:10	Discussion	
Coffee break		
10:30-11:15	Use of intermediate and surrogate endpoints in trials - S. Litière (BE)	
11:15-12:00	Design and analysis of phase II trials, role of randomization - R. Parker (USA)	
12:00-12:10	Discussion	
Lunch		
13:15-14:00	Predictive and prognostic factors in clinical trials - S. Halabi (USA)	
14:00-14:45	Diagnostic tests - S. Litière (BE)	
14:45-14:55	Discussion	
Coffee break		
15:15-16:00	Development of validation of gene signatures : experience in oncology - S. Halabi (USA)	
16:00-17:00	Paper discussion (Clinical trials design/analysis/ endpoints) - All speakers	

FACULTY

INTERNATIONAL FACULTY



LAURENCE COLLETTE European Organisation for Research and Treatment

of Cancer (EORTC), Belgium



ROBERT PARKER Director of Biometry, Massachusetts General

Hospital, United States



European Organisation for Research and

Treatment of Cancer (EORTC), Belgium



Duke University, US

LOCAL FACULTY

ALEJANDRO MOHAR BETANCOURT INCan, Mexico

TONATIHU BARRIENTOS INCan, Mexico

DAY 3 BIOMARKERS AND CLINICAL TRIALS

Saturday 21st, November 2015

8:30-09:15 Integration of biomarkers in phase II/III clinical trial designs - S. Halabi (US)

09:15-10:00 Adaptive clinical trial designs - S. Litière (BE)

10:00-10:10 Discussion

Coffee break

11:45-12:00

10:30-11:00 Introduction to Meta-analysis - T. Barrientos (MX)

11:00-11:45 Case studies and interpretation of results - All participants

> Group discussion with questions and answers - All speakers

12:30-12:35 Closing remarks – G. Werutsky (BR)

ENDORSING SOCIETIES /INSTITUTIONS

Support for this educational activity is provided by:







This is a LACOG

Under the auspices of the EORTC

